A Novartis Veteran Takes the Helm at Jiuzhou Pharmaceutical: Chinese CXOs Begin the Second Lesson After Buying MNC Assets

Xue Yingzhou, just appointed President of Jiuzhou Pharmaceutical, spent the first half of his career at Novartis rising to production director, supply-chain director and technical-service director; after Jiuzhou acquired Suzhou Novartis for about RMB 790M in 2019, he moved with the plant and ran its core subsidiary Ruibo Suzhou for seven years. Executive VP Cai Wanyu, appointed in the same batch, brings nearly 40 years of manufacturing management. The message is industry-wide: buying MNC assets in China is lesson one; internalising the acquirer's operating DNA is lesson two — the one that decides customer concentration and commercial-order execution.

A personnel announcement from Jiuzhou Pharmaceutical in late October drew more industry discussion than its headline suggested: Xue Yingzhou was appointed President of the company. His résumé has a clean dividing line — the first half at Novartis, rising to production director, supply-chain director and technical-service director; the second half after Jiuzhou acquired 100% of Suzhou Novartis in 2019 for about RMB 790M (net of divested technology and drug-development assets), when he moved with the plant to become general manager of the core subsidiary Ruibo Suzhou, a post he held for seven years before entering the listed company's top management.

Executive VP Cai Wanyu, appointed in the same batch, brings nearly 40 years of manufacturing management experience and was a core member of the National Science and Technology Progress First Prize-winning icotinib industrialisation project; fellow Executive VP LI Yuanqiang comes from a multinational R&D background. Three operations-oriented executives entering the core management team in one appointment round is not routine turnover — it is an organisational signal.

Lesson one: buy the assets, lock the orders

Go back to the 2019 transaction. Alongside the acquisition, Jiuzhou signed a manufacturing and supply agreement: for five years after closing, the acquired entity would supply Novartis with the APIs or intermediates of three products (in heart failure, breast cancer and leukaemia), extendable by another five years subject to conditions. It is the classic buy-assets-plus-lock-orders structure — a Chinese specialty-API maker gaining direct entry into a global major's commercial API supply chain in one deal.

It worked: Novartis has remained Jiuzhou's largest customer, at 56.65% of annual sales in 2024 and 54.50% in 2025. More than half of revenue tied to one customer is both the ceiling and the Achilles heel of that structure. As we noted in our 10 October-24 read of Jiuzhou's Q3, the order mix is diversifying — TIDES backlog above RMB 5B, small-molecule new projects up 25% — but the commercial base remains the Novartis system.

Lesson two: internalising the acquirer's operating DNA

The company's official description of Xue points at one thing: years of global pharmaceutical operations, supply-chain and technical-service practice inside the Novartis system, and a deep understanding of MNC customer needs. Behind it lies a judgement the industry has validated repeatedly: what changes hands at closing is plant, licences and equipment — but the real capacity is the operating system that stably delivers projects: change control, deviation management, supply-chain coordination, alignment with global quality systems. None of that sits on the balance sheet. It sits in people.

Putting a manager who grew up in Novartis manufacturing and then spent seven years running the acquired site into the president's chair means Jiuzhou is converting that operating DNA from a subsidiary's inheritance into a company-wide capability. The Q3 report showed overall CDMO utilisation around 70%, above 80% at Ruibo Suzhou, with new commercial lines there due in the second half of 2027 — and the question the appointment must answer is who guarantees that the next capacity cycle delivers multi-client commercial projects to non-Novartis quality expectations.

This is not an isolated case. Chinese CXOs have taken over MNC assets in China repeatedly over the past decade, and the pattern holds: lesson one (buy assets, lock orders) sets the starting point; lesson two (internalise operations, diversify the customer base) sets the ceiling. Companies that stop at lesson one become big customers' small suppliers. Companies that finish lesson two earn the right to talk about platforms.

Editorial note: people are the cheapest — and the most expensive — capacity

Three layers of transmission worth recording. First, the answer to customer concentration is not to take fewer Novartis orders but to standardise the operating and quality capability built while serving Novartis and sell it to the second and third MNC — which is exactly the business logic of putting a Novartis-system executive at the centre of decision-making. Second, execution behind the TIDES narrative: Jiuzhou added 20 TIDES projects in the nine months and grew solid-phase peptide capacity more than threefold in the first half, but after the reactors are built the scarce resource is never steel — it is teams that can manage GMP deviations and global audits at commercial scale; the appointment is, in effect, installing the software for the hardware. Third, a migration of the valuation anchor: as the market starts pricing second-tier CDMOs on order-to-revenue conversion, management execution moves from qualitative impression to valuation variable, and this appointment is a positive statement on that axis.

For readers tracking the Chinese CXDMO landscape, the weight of this personnel news is that it concedes a plain industry fact: the first valuation story of Chinese CXOs (acquisitions, order lock-ins) has been told, and the ticket to the second story is operating certainty. Whoever converts acquired DNA into their own muscle first will sit at the table when the next round of commercial orders is allocated.